Durrant Pate/Contributor

St Catherine-based pharmaceutical company, R.A. Williams Distributors, which is celebrating over one year as a publicly listed company, has more than doubled its year-over-year profit during the third quarter ended January 31, 2026.

Factoring in finance costs of $19.38 million, R.A. Williams achieved a net profit of J$33.51 million for the quarter, more than doubling the $14.17 million booked in the comparative period last year. Earnings per share for Q3 increased to J$0.017, up from J$0.008.

The combination of healthy revenue growth and enhanced operational efficiency enabled the company to record an operating profit of $52.87 million for the quarter, almost doubling the $28.58 million achieved last year. Enhanced cost management initiatives were instrumental to the company’s strong quarterly performance.

Cost-cutting measures bearing fruit

A major highlight of the quarter was the tangible result of management’s active drive to improve cost control, a core focus outlined at the close of the second quarter. Total operating expenses for the period were successfully reduced to $162.25 million, an improvement from the $175.50 million in 2025. 

This overall reduction was primarily driven by a significant decrease in administrative and general expenses, which fell to $98.68 million compared to $114.56 million year-over-year. This operational efficiency bolstered margins, effectively offsetting the rise in direct costs associated with surging sales volumes. 

“After the pressures we faced last quarter, we focused on strengthening our operations, controlling costs, and ensuring that our products remained consistently available across the island,” explains CEO Audley Reid.

According to him, “By keeping a close eye on our resources and supporting our teams on the ground, we were able to recover quickly. These efforts have allowed us to return to strong growth while continuing to provide reliable service to our customers… profitability is only meaningful when it supports long-term impact. We are reinvesting in our operations and deepening engagement with our partners to ensure that our growth benefits shareholders and the wider healthcare community alike.”

Total assets stood at $1.63 billion, up from $1.44 billion in the same period last year, while shareholders’ equity increased to $774.9 million, compared with $763.4 million at January 31, 2025.  Higher assets and equity indicate that earnings generated by the business are being retained and used to strengthen operations and support continued growth in pharmaceutical distribution.

Company Chairman John Bailey reports, “This strong rebound in third-quarter profitability validates the Board’s confidence in the Company’s long-term strategy. The targeted investments made during the first half of the year in brand visibility, infrastructure, and expanding our product portfolio, such as our entry into new therapeutic and wellness categories, are now yielding tangible returns. As we progress into the final quarter of the financial year, management will continue to prioritise long-term revenue growth, careful management of trade partnerships, and deepened engagement with healthcare professionals across Jamaica.”